Related references
Note: Only part of the references are listed.Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial
Roela Sadushi-Kolici et al.
LANCET RESPIRATORY MEDICINE (2019)
Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study
J. Gerry Coghlan et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2018)
Preclinical Pharmacology and Pharmacokinetics of Inhaled Hexadecyl-Treprostinil (C16TR), a Pulmonary Vasodilator Prodrug
Michel R. Corboz et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2017)
Targeted drugs for pulmonary arterial hypertension: a network meta-analysis of 32 randomized clinical trials
Xiao-Fei Gao et al.
PATIENT PREFERENCE AND ADHERENCE (2017)
An implantable pump Lenus pro® in the treatment of pulmonary arterial hypertension with intravenous treprostinil
Marcin Kurzyna et al.
BMC PULMONARY MEDICINE (2017)
Management of prostacyclin side effects in adult patients with pulmonary arterial hypertension
Martha Kingman et al.
PULMONARY CIRCULATION (2017)
Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges
Annie-Christine Lajoie et al.
PULMONARY CIRCULATION (2017)
Critical care management of pulmonary hypertension
R. Condliffe et al.
BJA EDUCATION (2017)
Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension A Meta-analysis of Randomized Controlled Trials
Huan-long Liu et al.
CHEST (2016)
Comparative Efficacy and Safety of Prostacyclin Analogs for Pulmonary Arterial Hypertension A Network Meta-Analysis
Huijun Zhang et al.
MEDICINE (2016)
Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis
Annie Christine Lajoie et al.
LANCET RESPIRATORY MEDICINE (2016)
Practical considerations for therapies targeting the prostacyclin pathway
Harrison W. Farber et al.
EUROPEAN RESPIRATORY REVIEW (2016)
Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension
Tetsuo Asaki et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Selexipag for the Treatment of Pulmonary Arterial Hypertension
Olivier Sitbon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: Role of membrane versus nuclear receptors
Lucie H. Clapp et al.
PROSTAGLANDINS & OTHER LIPID MEDIATORS (2015)
The limits of oral therapy in pulmonary arterial hypertension management
Qian-Qian Liu et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2015)
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement
David Moher et al.
SYSTEMATIC REVIEWS (2015)
Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension
Irene M. Lang et al.
EUROPEAN RESPIRATORY REVIEW (2015)
Prostanoid receptors and acute inflammation in skin
Hirofumi Hohjoh et al.
BIOCHIMIE (2014)
The role of vagal neurocircuits in the regulation of nausea and vomiting
Tanja Babic et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2014)
Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients Receiving Background Endothelin Receptor Antagonist and Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C2 Study) A Randomized Controlled Trial
Victor F. Tapson et al.
CHEST (2013)
Efficacy and Safety of Oral Treprostinil Monotherapy for the Treatment of Pulmonary Arterial Hypertension A Randomized, Controlled Trial
Zhi-Cheng Jing et al.
CIRCULATION (2013)
Differential actions of the prostacyclin analogues treprostinil and iloprost and the selexipag metabolite, MRE-269 (ACT-333679) in rat small pulmonary arteries and veins
N. N. Orie et al.
PROSTAGLANDINS & OTHER LIPID MEDIATORS (2013)
The Minimal Important Difference in the 6-Minute Walk Test for Patients with Pulmonary Arterial Hypertension
Stephen C. Mathai et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2012)
Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: Treprostinil is a potent DP1 and EP2 agonist
Brendan J. Whittle et al.
BIOCHEMICAL PHARMACOLOGY (2012)
Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients on Background Endothelin Receptor Antagonist and/or Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C Study) A Randomized Controlled Trial
Victor E. Tapson et al.
CHEST (2012)
Validation of 6-Minute Walk Distance as a Surrogate End Point in Pulmonary Arterial Hypertension Trials
Nicole B. Gabler et al.
CIRCULATION (2012)
Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension
Gerald Simonneau et al.
EUROPEAN RESPIRATORY JOURNAL (2012)
Efficacy and safety of prostacyclins therapy in pulmonary arterial hypertension: A meta-analysis
Xi-Qian Xing et al.
AFRICAN JOURNAL OF PHARMACY AND PHARMACOLOGY (2011)
Role of prostanoid IP and EP receptors in mediating vasorelaxant responses to PGI2 analogues in rat tail artery: Evidence for Gi/o modulation via EP3 receptors
Nelson N. Orie et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2011)
Interpretation of random effects meta-analyses
Richard D. Riley et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Smooth Muscle Proliferation and Role of the Prostacyclin (IP) Receptor in Idiopathic Pulmonary Arterial Hypertension
Emilia Falcetti et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2010)
Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: A placebo-controlled trial
Jagdish Hiremath et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2010)
Subcutaneous treprostinil in pulmonary arterial hypertension: Practical considerations
Michael A. Mathier et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2010)
Addition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial Hypertension A Randomized Controlled Clinical Trial
Vallerie V. McLaughlin et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis
Christopher J. Ryerson et al.
RESPIRATORY RESEARCH (2010)
Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: An experience-based review
Ronald J. Oudiz et al.
AMERICAN HEART JOURNAL (2009)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
ANNALS OF INTERNAL MEDICINE (2009)
Long-term outcome with intravenous iloprost in pulmonary arterial hypertension
M. M. Hoeper et al.
EUROPEAN RESPIRATORY JOURNAL (2009)
The mechanism and mitigation of niacin-induced flushing
V. S. Kamanna et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2009)
Role of the prostanoid EP4 receptor in iloprost-mediated vasodilatation in pulmonary hypertension
Ying-Ju Lai et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2008)
Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: A controlled trial
Melvyn Rubenfire et al.
CHEST (2007)
2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug
Keiichi Kuwano et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Prostaglandin E2 is required for ultraviolet B-induced skin inflammation via EP2 and EP4 receptors
Kenji Kabashima et al.
LABORATORY INVESTIGATION (2007)
Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil
R. J. Barst et al.
EUROPEAN RESPIRATORY JOURNAL (2006)
Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension
Vallerie V. McLaughlin et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2006)
Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans
K Cheng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Prostanoid therapy for pulmonary arterial hypertension
DB Badesch et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2004)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
Beraprost therapy for pulmonary arterial hypertension
RJ Barst et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2003)
Efficacy and safety of treprostinil: An Epoprostenol analog for primary pulmonary hypertension
VV McLaughlin et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2003)
Inhaled iloprost for severe pulmonary hypertension
H Olschewski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Quantifying heterogeneity in a meta-analysis
JPT Higgins et al.
STATISTICS IN MEDICINE (2002)
Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension:: With pulmonary arterial hypertension:: A randomized, double-blind, placebo-controlled trial
N Galiè et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2002)
Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension - A double-blind, randomized, placebo-controlled trial
G Simonneau et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2002)
Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery
LH Clapp et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2002)
Correlates of health-related quality of life in patients with heart failure
C Westlake et al.
HEART & LUNG (2002)
EQ-5D: a measure of health status from the EuroQol Group
R Rabin et al.
ANNALS OF MEDICINE (2001)
Share Paper
